Investigators in Canada found no evidence to support extending treatment for Clostridioides difficile infection for patients on concurrent antibiotics

Clostridioides difficile infection (CDI) is the most lethal of the five CDC urgent public health treats, resulting in 12,800 annual deaths in the United States alone [Antibiotic Resistance Threats in the United States, 2019 (2019), www.cdc.gov/DrugResistance/Biggest-Threats.html]. The …

The infection causes diarrhea and inflammation of the colon, and it can be difficult to get rid of it.

This is a literature review describes Crohn's disease (CD) concomitant with breast cancer and summarizes possible common pathogenic mechanisms shared by the two diseases involving the IL-17 and NF-κB signaling pathways. Inflammatory cytokines including TNF-α and Th17 cells in CD patients can induce …

Racial differences in Clostridioides difficile infection (CDI) outcomes have been reported. In this study, minoritized patients with CDIs had prolonged hospitalizations and increased intensive care unit admissions. Chronic kidney disease was shown to partially mediate the relationship between …

Emergency Medicine’s #1 Journal Publication: Clinical advances and trends from the most trusted emergency medical news source in emergency medicine.

Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infections. Its incidence has increased during the last decade in the community among individuals with no previous risk factors; however, morbidity and mortality are still considered high in elderly patients. Oral V …

Clostridioides difficile infection (CDI) causes substantial morbidity and mortality worldwide with limited antibiotic treatment options. Ridinilazole is a precision bisbenzimidazole antibiotic being developed to treat CDI and reduce unacceptably high rates of infection recurrence in patients. Althou …

Clostridioides difficile infections (CDIs) remain a healthcare problem due to high rates of relapsing/recurrent CDIs (rCDIs). Breakdown of colonization resistance promoted by broad-spectrum antibiotics and the persistence of spores contribute to rCDI. Here, we demonstrate antimicrobial activity of t …

C. difficile or Clostridioides difficile infection (CDI) is currently one of the major causes of epidemics worldwide. Toxin B from Clostridioides difficile toxin B (TcdB) infection is the main target protein inhibiting CDI recurrence. Clinical research suggested that bezlotoxuma …

No significant difference in rates of recurrence or new onset VRE were observed between SDT and EDT in HA-CDI patients.

A team of investigators from Mass General Brigham’s founding members, Brigham and Women’s Hospital and Massachusetts General Hospital, has identified metabolic strategies used by Clostridioides difficile to rapidly colonize the gut and new treatments for it.

A hospital reviewed both treatments in a real-world clinical setting to determine the effectiveness in preventing early and late recurrences.

A live biotherapeutics product used alongside antibiotics can help combat C. difficile infection (CDI).

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

There are minimal differences between TAC and DLI with antegrade colonic lavage for fulminant CDI in terms of postoperative morbidity and mortality. Healthcare resource utilization, however, is significantly improved when patients undergo TAC as evidenced by clinically important decreases in total a …

How should we determine the role of bezlotoxumab for pediatric Clostridioides difficile infection?

30.5% absolute risk reduction versus placebo with eight-strain oral product

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).

From travel concerns to feeling isolated, discover how three UC warriors overcame their fears.

Can't wait to speak on the topic of "#MedicalGaslighting & #Cdiff: Utilizing Your Voice Effectively."#infectiousdisease #healthcare #advocacy #awareness #LetsSaveLives https://t.co/oLXKAfeCed— Dr. Melissa Geraghty, Psy.D. (She/Her/Dr)🦓🦒🦄😷♿ (@MindfulDrG) April 19, 2023

With the approval and development of narrow-spectrum antibiotics for the treatment of Clostridioides difficile infection (CDI), the primary endpoint for treatment success of CDI antibiotic treatment trials has shifted from treatment response at end of therapy to sustained response 30 days after comp …

Sure I couldn’t be left out from todays @RCSI_Micro showing @ESCMID #ECCMID23 - great session on #cdiff in children with co chair Alessia Franceschi (Italy) & our incredible speakers Marcella Krutova (Czech republic) & Anne Gonzales-Luna (US) @iscm_micro @RCSI_Irl @hpscireland pic.twitter.com/Feumq4P6XW— Prof. Fidelma Fitzpatrick (@FfitzP) April 15, 2023

In-the-last-decade-we-have-started-to-understand-the-critical-components-of-the-gut-microbiome-that-prevent-C-difficile-expansion

The stubborn superbug Clostridium difficile, or C. diff, may have met its match. A esearcher is reporting the first well-controlled study to demonstrate the effectiveness of a new medicine for patients with the debilitating recurrent infection and disease.

Nitrofurantoin use and a history of malignancy were significantly associated with recurrent infections, which increased during 2019–2020.

With the approval and development of narrow-spectrum antibiotics for the treatment of Clostridioides difficile infection (CDI), the primary endpoint for treatment success of CDI antibiotic treatment trials has shifted from treatment response at end of therapy to sustained response 30 days after completed therapy. The current definition of a successful response to treatment (three or fewer unformed bowel movements [UBMs] per day for 1–2 days) has not been validated, does not reflect CDI management, and could impair assessments for successful treatment at 30 days.

Our study confirms the efficacy of BEZ+SoC for the prevention of rCDI and death in a real-world setting. BEZ should be routinely considered among participants at high risk of rCDI regardless of age, type of CDI therapy (vancomycin vs. fidaxomicin) and number of risk factors.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

A live biotherapeutics product used alongside antibiotics can help combat C. difficile infection (CDI).